Upstream Bio, Inc. (UPB) stock price, financials & research

Regular session · ET · Market data may be delayed.

GoAI snapshot

Jul 10, 2026

35/ 100

GoAI Score

Sell

Valuation

51

Fair Value

Sentiment

42

Mixed

Risk

71

High Risk

Momentum

27

Weakening

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

Company profile

Company website

Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: E. Rand Sutherland
Listed since: Oct 11, 2024
Employees: 75

Market position

Day range

Current $4.542

$4.54$4.68

52-week range

Current $4.542

$4.365$33.68

Open: $4.54
Previous close: $4.55
Volume: 175.82K; 0.27× average
Average volume: 658.82K; Average daily volume
Market cap: 247.18M USD
Beta: 1.39; Market reference 1
50-day average: $6.115; -25.72% below average
200-day average: $11.3362; -59.93% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 1.36B USD
P/E (TTM): -1.57×
P/B (TTM): 0.91×
P/S (TTM): 78.27×
EV / EBITDA: -9.51×
Earnings yield: -9.81%
Free cash flow yield: -9.12%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 98.45%
Operating margin: -5382.65%
Net margin: -4955.67%
Return on equity: -42.22%
Return on assets: -40.55%
Return on invested capital: -47.02%

Financial health

Debt / equity: 0×
Current ratio: 26.15×
Altman Z-score: 12
Piotroski F-score: 2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin

Income trends

Revenue

2.85M USD+20.42%

Operating income

−160.36M USD-106.21%

Net income

−143.44M USD-128.39%

Financial statements: Income statement
Metric (USD)	FY2025	FY2024	FY2023	FY2022
Revenue	2.85M USD	2.37M USD	2.38M USD	1.21M USD
Gross profit	2.85M USD	2.37M USD	2.38M USD	1.21M USD
Research and development	136.81M USD	62.97M USD	31.8M USD	18.66M USD
Selling, general, and administrative	26.41M USD	17.17M USD	10.7M USD	6.46M USD
Operating expenses	163.22M USD	80.13M USD	42.49M USD	25.12M USD
Interest income	16.93M USD	12.12M USD	4.17M USD	205K USD
Depreciation and amortization	188K USD	89K USD	60K USD	7K USD
Operating income	−160.36M USD	−77.76M USD	−40.11M USD	−23.91M USD
Net income	−143.44M USD	−62.81M USD	−20.54M USD	−23.87M USD

Company facts updated Oct 9, 2026.

Earnings

EPS beat rate: 38%; 3 beats, 4 misses, 1 met estimate
Average EPS surprise: -147.69%; 8 comparable reports
Latest EPS result: -0.73; Estimate -0.78 · Beat by 6.41%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$25.00

450.42% upside

Past 12 months12-month forecastHigh $25.00Average $25.00Low $25.00

Rating distribution

5 ratings

Strong buy00%

Buy360%

Hold240%

Sell00%

Strong sell00%

Recent analyst actions

5 institutions

HC Wainwright & Co.maintainBuySep 2, 2026

Truist SecuritiesmaintainBuyAug 12, 2026

MizuhomaintainOutperformMay 14, 2026

Evercore ISI GroupdowngradeOutperformIn LineMar 27, 2026

UPB news

defenseworld.netOct 5, 2026

Analyzing Upstream Bio (NASDAQ:UPB) and Keros Therapeutics (NASDAQ:KROS)

Keros Therapeutics (NASDAQ: KROS - Get Free Report) and Upstream Bio (NASDAQ: UPB - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on…

Read source

marketwatch.comSep 21, 2026

These beaten-down stocks could bounce back in January, if history is any guide

Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore good bets to bounce back in the new year

Read source

globenewswire.comSep 8, 2026

Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026

– Verekitug, 100 mg dosed every 12 weeks, reduced AAER by 56% compared to placebo in patients with severe asthma – – Verekitug also delivered clinically meaningful improvements in lung function (FEV 1 ) and exhaled…

Read source

globenewswire.comSep 1, 2026

Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP

– Following productive FDA discussions, Upstream Bio will study 400 mg of verekitug administered every 12 weeks, versus placebo, in severe asthma and CRSwNP with one pivotal Phase 3 trial in each indication – – The…

Read source

gurufocus.comAug 19, 2026

Fannie Mae Announces Sale of Non-Performing Loans

Fannie Mae Announces Sale of Non-Performing Loans PR Newswire WASHINGTON, Aug. 19, 2026

Read source

zacks.comAug 11, 2026

Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates

Upstream Bio, Inc. (UPB) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to a loss of $0.74 per share a year ago.

Read source